Browse

You are looking at 1 - 10 of 21 items

L I Astaf’eva N.N. Burdenko National Medical Research Centre of Neurosurgery, Moscow, Russian Federation

Search for other papers by L I Astaf’eva in
Google Scholar
PubMed
Close
,
Y G Sidneva N.N. Burdenko National Medical Research Centre of Neurosurgery, Moscow, Russian Federation

Search for other papers by Y G Sidneva in
Google Scholar
PubMed
Close
,
B A Kadashev N.N. Burdenko National Medical Research Centre of Neurosurgery, Moscow, Russian Federation

Search for other papers by B A Kadashev in
Google Scholar
PubMed
Close
,
P L Kalinin N.N. Burdenko National Medical Research Centre of Neurosurgery, Moscow, Russian Federation

Search for other papers by P L Kalinin in
Google Scholar
PubMed
Close
,
G A Melnichenko National Medical Research Centre of Endocrinology, Moscow, Russian Federation

Search for other papers by G A Melnichenko in
Google Scholar
PubMed
Close
, and
S A Agadzhanian Department of English Language for Natural Faculties, Lomonosov Moscow State University, Moscow, Russian Federation

Search for other papers by S A Agadzhanian in
Google Scholar
PubMed
Close

Summary

A 32-year-old woman presented with primary amenorrhoea, prolactin (PRL) level of 154 150 mIU/L and was diagnosed with a giant pituitary adenoma measuring maximum 6.2 cm. Cabergoline (CAB) treatment at a dose of 0.5 mg/week was prescribed to the patient. The treatment decreased the tumour size after 3 months (MRI scans of the brain) and brought back to normal the level of the PRL (345 mIU/L) after 6 months of CAB treatment. After 7 months of CAB treatment, menarche was achieved, and after 12 months, the patient became pregnant. She discontinued taking CAB at 4-week gestation. The pregnancy resulted in a missed miscarriage at 6–7 weeks; an abortion was conducted by the vacuum aspiration method. The MRI scans of the brain did not show any tumour enlargement. After 18 months from the start of the treatment the patient got pregnant for the second time. At 25-week gestation an MRI scan of the brain was conducted which did not show any increase in the tumour size. At 38 weeks the patient delivered a healthy full-term girl via C-section. The patient chose not to breastfeed and resumed CAB therapy after the delivery. During the treatment, the PRL level returned to the normal range and the menstrual cycle was restored. After 3 years the patient got pregnant for the third time. The patient did not receive CAB during the pregnancies; the examination did not show any tumour enlargement. Further MRI scans did not show any tumour growth. CAB therapy was effective in normalization of the PRL level, tumour shrinkage, menarche and pregnancy-induction which led to the birth of healthy children in a woman with primary amenorrhoea and a giant prolactinoma invading the skull base bones.

Learning points:

  • Giant prolactinomas are very rarely found in women.

  • Cabergoline therapy can be effective in the normalization of the PRL level, tumour shrinkage, menarche induction in a woman with primary amenorrhoea, and giant prolactinoma.

  • Cabergoline therapy can be effective in pregnancy induction which leads to the birth of children in a woman with giant prolactinoma.

  • Cabergoline discontinuation did not trigger tumour enlargement during pregnancy.

Open access
Ellena Cotton Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK
Specialist Medicine, Manchester University Foundation Trust, Manchester, UK

Search for other papers by Ellena Cotton in
Google Scholar
PubMed
Close
and
David Ray Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK

Search for other papers by David Ray in
Google Scholar
PubMed
Close

Summary

A young woman carrying germline DICER1 mutation was discovered to have a pituitary microprolactinoma when she became amenorrhoic. The mutation was identified as a result of family screening following the early death of the patient’s daughter with ovarian cancer. The patient was in follow-up screening for thyroid disease, and investigations were initiated when she became amenorrhoic. MR scan revealed a 6 mm diameter pituitary microadenoma and raised prolactin. The prolactin was efficiently suppressed with low-dose cabergoline, and her menstrual cycles resumed. Dicer is an RNase enzyme, which is essential for processing small non-coding RNAs. These molecules play pleiotropic roles in regulating gene expression, by targeting mRNA sequences for degradation. DICER1 plays different roles depending on cell context, but is thought to be a functional tumour suppressor gene. Accordingly, germline mutation in one DICER1 allele is insufficient for oncogenesis, and a second hit on the other allele is required, as a result of postnatal somatic mutation. Loss of DICER1 is linked to multiple tumours, with prominent endocrine representation. Multinodular goitre is frequent, with increased risk of differentiated thyroid cancer. Rare, developmental pituitary tumours are reported, including pituitary blastoma, but not reports of functional pituitary adenomas. As DICER1 mutations are rare, case reports are the only means to identify new manifestations and to inform appropriate screening protocols.

Learning points:

  • DICER1 mutations lead to endocrine tumours.

  • DICER1 is required for small non-coding RNA expression.

  • DICER1 carriage and microprolactinoma are both rare, but here are reported in the same individual, suggesting association.

  • Endocrine follow-up of patients carrying DICER1 mutations should consider pituitary disease.

Open access
Benedetta Zampetti Endocrinology Unit, Niguarda Hospital, Milan, Italy

Search for other papers by Benedetta Zampetti in
Google Scholar
PubMed
Close
,
Giorgia Simonetti Neurooncology Unit, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy

Search for other papers by Giorgia Simonetti in
Google Scholar
PubMed
Close
,
Roberto Attanasio Endocrinology Service, Galeazzi Institute IRCCS, Milan, Italy

Search for other papers by Roberto Attanasio in
Google Scholar
PubMed
Close
,
Antonio Silvani Neurooncology Unit, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy

Search for other papers by Antonio Silvani in
Google Scholar
PubMed
Close
, and
Renato Cozzi Endocrinology Unit, Niguarda Hospital, Milan, Italy

Search for other papers by Renato Cozzi in
Google Scholar
PubMed
Close

Summary

We describe the 20-year course of a 63-year-old male with a macroprolactinoma that acquired resistance to treatment and aggressive behavior after a 4-year successful treatment with cabergoline. He was submitted to multiple surgical resections by a skilled surgeon, fractionated radiotherapy and was eventually treated with temozolomide. After a first 6-month standard cycle, a relapse occurred and he was treated again successfully.

Learning points:

  • Prolactinomas are the most frequent type of pituitary adenoma.

  • They usually have a benign course.

  • In most cases dopamine-agonist drugs, mainly cabergoline, are first-line (and usually only) treatment.

  • Occasionally prolactinomas can have or acquire resistance to treatment and/or aggressive behavior.

  • Temozolomide (TMZ), an oral alkylating drug, can be effective in such aggressive tumors.

  • Multimodal treatment (surgery, radiation, cabergoline and TMZ) is warranted in aggressive pituitary tumors.

  • We describe here successful rechallenge with TMZ after relapse occurring 18 months after a first TMZ cycle.

Open access
Yew Wen Yap Leighton Hospital, Crewe, Crewe, UK

Search for other papers by Yew Wen Yap in
Google Scholar
PubMed
Close
,
Steve Ball Manchester University NHS Foundation Trust, Manchester, UK

Search for other papers by Steve Ball in
Google Scholar
PubMed
Close
, and
Zubair Qureshi Leighton Hospital, Crewe, Crewe, UK

Search for other papers by Zubair Qureshi in
Google Scholar
PubMed
Close

Summary

The coexistence of primary hypothyroidism and thyroid-stimulating hormone (TSH)-stimulating pituitary macroadenoma can be a rare occurrence and can make diagnosis very challenging. We describe a case of a 44-year-old female with a history of fatigue, poor concentration, weight gain and amenorrhoea together with biochemical evidence of primary autoimmune hypothyroidism. Her initial TSH levels were elevated with low normal free thyroxine (T4) levels. Levothyroxine treatment was initiated and the dose was gradually titrated to supraphysiologic doses. This led to the normalisation of her TSH levels but her free T4 and triiodothyronine (T3) levels remained persistently elevated. This prompted a serum prolactin check which returned elevated at 2495 µ/L, leading onto pituitary imaging. A MRI of the pituitary gland revealed a pituitary macroadenoma measuring 2.4 × 2 × 1.6 cm. Despite starting her on cabergoline therapy with a reduction in her prolactin levels, her TSH levels began to rise even further. Additional thyroid assays revealed that she had an abnormally elevated alpha subunit at 3.95 (age-related reference range <3.00). This corresponded to a thyroid-secreting hormone pituitary macroadenoma. She went on to have a transphenoidal hypophysectomy. Histology revealed tissues staining for TSH, confirming this to be a TSH-secreting pituitary macroadenoma. This case highlighted the importance of further investigations with thyroid assay interferences, heterophile antibodies, alpha subunit testing and anterior pituitary profile in cases of resistant and non-resolving primary hypothyroidism.

Learning points:

  • Levothyroxine treatment in primary hypothyroidism can potentially unmask the presence of a latent TSH-secreting pituitary macroadenoma, which can make diagnosis very challenging.

  • A high index of suspicion should prompt clinicians to further investigate cases of primary hypothyroidism which despite increasing doses of levothyroxine treatment with normalisation of TSH, the free T4 and T3 levels remain persistently elevated.

  • Clinicians should consider investigating for adherence to levothyroxine, thyroid assay interference, heterophile antibodies, TSH dilution studies, alpha subunit and anterior pituitary profile testing to further clarity the diagnosis in these patients.

  • Although coexistent cases of TSHoma with primary hypothyroidism are rare, it should always be in the list of differential diagnoses in cases of unresolving primary hypothyroidism.

Open access
Wael M Almistehi Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia

Search for other papers by Wael M Almistehi in
Google Scholar
PubMed
Close
and
Mussa H Almalki Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia
King Fahad Medical City, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

Search for other papers by Mussa H Almalki in
Google Scholar
PubMed
Close

Summary

Giant prolactinomas are a rare entity; during pregnancy, the risk for complications associated with these tumors is higher. Here, we report a case of a young woman who had an invasive, giant prolactinoma post resection with residual disease who became pregnant. This patient was treated with cabergoline to prevent tumor expansion in pregnancy, resulting in the uneventful delivery of a healthy baby boy.

Learning points:

  • Giant prolactinoma can cause both diagnostic and therapeutic challenges given their atypical presentation.

  • Accurate diagnosis is paramount to avoid unnecessary surgical intervention or pituitary irradiation.

  • This case demonstrates the effectiveness and safety of CAB therapy during pregnancy.

Open access
Michelle Maher Endocrinology, Imperial College Healthcare NHS Trust, London, UK
National University of Ireland, Galway, Ireland

Search for other papers by Michelle Maher in
Google Scholar
PubMed
Close
,
Federico Roncaroli University of Manchester, Manchester, UK

Search for other papers by Federico Roncaroli in
Google Scholar
PubMed
Close
,
Nigel Mendoza Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Nigel Mendoza in
Google Scholar
PubMed
Close
,
Karim Meeran Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Karim Meeran in
Google Scholar
PubMed
Close
,
Natalie Canham Liverpool Womens NHS Foundation Trust, Liverpool, UK

Search for other papers by Natalie Canham in
Google Scholar
PubMed
Close
,
Monika Kosicka-Slawinska London North West Healthcare NHS Trust, London, UK

Search for other papers by Monika Kosicka-Slawinska in
Google Scholar
PubMed
Close
,
Birgitta Bernhard London North West Healthcare NHS Trust, London, UK

Search for other papers by Birgitta Bernhard in
Google Scholar
PubMed
Close
,
David Collier The William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Search for other papers by David Collier in
Google Scholar
PubMed
Close
,
Juliana Drummond The William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Search for other papers by Juliana Drummond in
Google Scholar
PubMed
Close
,
Kassiani Skordilis University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Edgbaston, Birmingham, UK

Search for other papers by Kassiani Skordilis in
Google Scholar
PubMed
Close
,
Nicola Tufton The Royal London Hospital, Barts Health NHS Trust, London UK

Search for other papers by Nicola Tufton in
Google Scholar
PubMed
Close
,
Anastasia Gontsarova Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Anastasia Gontsarova in
Google Scholar
PubMed
Close
,
Niamh Martin Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Niamh Martin in
Google Scholar
PubMed
Close
,
Márta Korbonits The William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Close
, and
Florian Wernig Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Florian Wernig in
Google Scholar
PubMed
Close

Summary

Symptomatic pituitary adenomas occur with a prevalence of approximately 0.1% in the general population. It is estimated that 5% of pituitary adenomas occur in a familial setting, either in isolated or syndromic form. Recently, loss-of-function mutations in genes encoding succinate dehydrogenase subunits (SDHx) or MYC-associated factor X (MAX) have been found to predispose to pituitary adenomas in co-existence with paragangliomas or phaeochromocytomas. It is rare, however, for a familial SDHx mutation to manifest as an isolated pituitary adenoma. We present the case of a pituitary lactotroph adenoma in a patient with a heterozygous germline SDHB mutation, in the absence of concomitant neoplasms. Initially, the adenoma showed biochemical response but poor tumour shrinkage in response to cabergoline; therefore, transsphenoidal surgery was performed. Following initial clinical improvement, tumour recurrence was identified 15 months later. Interestingly, re-initiation of cabergoline proved successful and the lesion demonstrated both biochemical response and tumour shrinkage. Our patient’s SDHB mutation was identified when we realised that her father had a metastatic paraganglioma, prompting genetic testing. Re-inspection of the histopathological report of the prolactinoma confirmed cells with vacuolated cytoplasm. This histological feature is suggestive of an SDHx mutation and should prompt further screening for mutations by immunohistochemistry and/or genetic testing. Surprisingly, immunohistochemistry of this pituitary adenoma demonstrated normal SDHB expression, despite loss of SDHB expression in the patient’s father’s paraganglioma.

Learning points:

  • Pituitary adenomas may be the presenting and/or sole feature of SDHB mutation-related disease.

  • SDHx mutated pituitary adenomas may display clinically aggressive behaviour and demonstrate variable response to medical treatment.

  • Histological evidence of intracytoplasmic vacuoles in a pituitary adenoma might suggest an SDH-deficient tumour and should prompt further screening for SDHx mutations.

  • Immunohistochemistry may not always predict the presence of SDHx mutations.

Open access
Anne de Bray Department of Endocrinology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Centre for Endocrinology, Diabetes & Metabolism, Birmingham Health Partners, Birmingham, UK
Institute for Metabolism and Systems Research, University of Birmingham, Birmingham, UK

Search for other papers by Anne de Bray in
Google Scholar
PubMed
Close
,
Zaki K Hassan-Smith Department of Endocrinology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Centre for Endocrinology, Diabetes & Metabolism, Birmingham Health Partners, Birmingham, UK

Search for other papers by Zaki K Hassan-Smith in
Google Scholar
PubMed
Close
,
Jamal Dirie Department of Endocrinology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Centre for Endocrinology, Diabetes & Metabolism, Birmingham Health Partners, Birmingham, UK

Search for other papers by Jamal Dirie in
Google Scholar
PubMed
Close
,
Edward Littleton Departments of Neurology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Search for other papers by Edward Littleton in
Google Scholar
PubMed
Close
,
Swarupsinh Chavda Departments of Radiology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Search for other papers by Swarupsinh Chavda in
Google Scholar
PubMed
Close
,
John Ayuk Department of Endocrinology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Centre for Endocrinology, Diabetes & Metabolism, Birmingham Health Partners, Birmingham, UK

Search for other papers by John Ayuk in
Google Scholar
PubMed
Close
,
Paul Sanghera Departments of Oncology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Search for other papers by Paul Sanghera in
Google Scholar
PubMed
Close
, and
Niki Karavitaki Department of Endocrinology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Centre for Endocrinology, Diabetes & Metabolism, Birmingham Health Partners, Birmingham, UK
Institute for Metabolism and Systems Research, University of Birmingham, Birmingham, UK

Search for other papers by Niki Karavitaki in
Google Scholar
PubMed
Close

Summary

A 48-year-old man was diagnosed with a large macroprolactinoma in 1982 treated with surgery, adjuvant radiotherapy and bromocriptine. Normal prolactin was achieved in 2005 but in 2009 it started rising. Pituitary MRIs in 2009, 2012, 2014 and 2015 were reported as showing empty pituitary fossa. Prolactin continued to increase (despite increasing bromocriptine dose). Trialling cabergoline had no effect (prolactin 191,380 mU/L). In January 2016, he presented with right facial weakness and CT head was reported as showing no acute intracranial abnormality. In late 2016, he was referred to ENT with hoarse voice; left hypoglossal and recurrent laryngeal nerve palsies were found. At this point, prolactin was 534,176 mU/L. Just before further endocrine review, he had a fall and CT head showed a basal skull mass invading the left petrous temporal bone. Pituitary MRI revealed a large enhancing mass within the sella infiltrating the clivus, extending into the left petrous apex and occipital condyle with involvement of the left Meckel’s cave, internal acoustic meatus, jugular foramen and hypoglossal canal. At that time, left abducens nerve palsy was also present. CT thorax/abdomen/pelvis excluded malignancy. Review of previous images suggested that this lesion had started becoming evident below the fossa in pituitary MRI of 2015. Temozolomide was initiated. After eight cycles, there is significant tumour reduction with prolactin 1565 mU/L and cranial nerve deficits have remained stable. Prolactinomas can manifest aggressive behaviour even decades after initial treatment highlighting the unpredictable clinical course they can demonstrate and the need for careful imaging review.

Learning points:

  • Aggressive behaviour of prolactinomas can manifest even decades after first treatment highlighting the unpredictable clinical course these tumours can demonstrate.

  • Escape from control of hyperprolactinaemia in the absence of sellar adenomatous tissue requires careful and systematic search for the anatomical localisation of the lesion responsible for the prolactin excess.

  • Temozolomide is a valuable agent in the therapeutic armamentarium for aggressive/invasive prolactinomas, particularly if they are not amenable to other treatment modalities.

Open access
W K M G Amarawardena Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
Department of Endocrinology, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK

Search for other papers by W K M G Amarawardena in
Google Scholar
PubMed
Close
,
K D Liyanarachchi Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
Department of Endocrinology, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK

Search for other papers by K D Liyanarachchi in
Google Scholar
PubMed
Close
,
J D C Newell-Price Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
Department of Endocrinology, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK

Search for other papers by J D C Newell-Price in
Google Scholar
PubMed
Close
,
R J M Ross Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK

Search for other papers by R J M Ross in
Google Scholar
PubMed
Close
,
D Iacovazzo Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, UK

Search for other papers by D Iacovazzo in
Google Scholar
PubMed
Close
, and
M Debono Department of Endocrinology, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK

Search for other papers by M Debono in
Google Scholar
PubMed
Close

Summary

The granulation pattern of somatotroph adenomas is well known to be associated with differing clinical and biochemical characteristics, and it has been shown that sparsely granulated tumours respond poorly to commonly used somatostatin receptor ligands (SRLs). We report a challenging case of acromegaly with a sparsely granulated tumour resistant to multiple modalities of treatment, ultimately achieving biochemical control with pasireotide. A 26-year-old lady presented with classical features of acromegaly, which was confirmed by an oral glucose tolerance test. Insulin-like growth factor 1 (IGF1) was 1710 µg/L (103–310 µg/L) and mean growth hormone (GH) was >600 U/L. MRI scan showed a 4 cm pituitary macroadenoma with suprasellar extension and right-sided cavernous sinus invasion. She underwent trans-sphenoidal pituitary surgery. Histology displayed moderate amounts of sparsely granular eosinophilic cytoplasm, staining only for GH. Postoperative investigations showed uncontrolled disease (IGF1:1474 µg/L, mean GH:228 U/L) and residual tumour in the cavernous sinus. She received external beam fractionated radiation. Over the years, she received octreotide LAR (up to 30 mg), lanreotide (up to 120 mg) two weekly, cabergoline, pegvisomant and stereotactic radiosurgery to no avail. Only pegvisomant resulted in an element of disease control; however, this had to be stopped due to abnormal liver function tests. Fifteen years after the diagnosis, she was started on pasireotide 40 mg monthly. Within a month, her IGF1 dropped and has remained within the normal range (103–310 µg/L). Pasireotide has been well tolerated, and there has been significant clinical improvement. Somatostatin receptor subtyping revealed a positivity score of two for both sst5 and sst2a subtypes.

Learning points:

  • Age, size of the tumour, GH levels on presentation, histopathological type and the somatostatin receptor status of the tumour in acromegaly should be reviewed in patients who poorly respond to first-generation somatostatin receptor ligands.

  • Tumours that respond poorly to first-generation somatostatin receptor ligands, especially sparsely granulated somatotroph adenomas, can respond to pasireotide and treatment should be considered early in the management of resistant tumours.

  • Patients with membranous expression of sst5 are likely to be more responsive to pasireotide.

Open access
Oscar D Bruno Division of Endocrinology
Fundacion de Endocrinologia

Search for other papers by Oscar D Bruno in
Google Scholar
PubMed
Close
,
Ricardo Fernández Pisani Division of Neurosurgery, Hospital de Clínicas, Universidad de Buenos Aires, Buenos Aires, Argentina

Search for other papers by Ricardo Fernández Pisani in
Google Scholar
PubMed
Close
,
Gabriel Isaac Division of Endocrinology

Search for other papers by Gabriel Isaac in
Google Scholar
PubMed
Close
, and
Armando Basso Division of Neurosurgery, Hospital de Clínicas, Universidad de Buenos Aires, Buenos Aires, Argentina

Search for other papers by Armando Basso in
Google Scholar
PubMed
Close

Summary

The role of mechanical forces influencing the growth of a pituitary adenoma is poorly understood. In this paper we report the case of a young man with hyperprolactinaemia and an empty sella secondary to hydrocephalia, who developed a macroprolactinoma following the relief of high intraventricular pressure.

Learning points:

  • The volume of a pituitary tumour may be influenced not only by molecular but also by local mechanical factors.

  • Intratumoural pressure, resistance of the sellar diaphragm and intracranial liquid pressure may play a role in the final size of a pituitary adenoma.

  • The presence of hydrocephalus may hide a pituitary macroadenoma.

Open access
Shinsuke Uraki The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

Search for other papers by Shinsuke Uraki in
Google Scholar
PubMed
Close
,
Hiroyuki Ariyasu The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

Search for other papers by Hiroyuki Ariyasu in
Google Scholar
PubMed
Close
,
Asako Doi The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

Search for other papers by Asako Doi in
Google Scholar
PubMed
Close
,
Hiroto Furuta The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

Search for other papers by Hiroto Furuta in
Google Scholar
PubMed
Close
,
Masahiro Nishi The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

Search for other papers by Masahiro Nishi in
Google Scholar
PubMed
Close
,
Takeshi Usui Department of Medical Genetics, Shizuoka General Hospital, Shizuoka City, Japan

Search for other papers by Takeshi Usui in
Google Scholar
PubMed
Close
,
Hiroki Yamaue The 2nd Department of Surgery, Wakayama Medical University, Wakayama, Japan

Search for other papers by Hiroki Yamaue in
Google Scholar
PubMed
Close
, and
Takashi Akamizu The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

Search for other papers by Takashi Akamizu in
Google Scholar
PubMed
Close

Summary

A 54-year-old man had gastrinoma, parathyroid hyperplasia and pituitary tumor. His family history indicated that he might have multiple endocrine neoplasia type 1 (MEN1). MEN1 gene analysis revealed a heterozygous germline mutation (Gly156Arg). Therefore, we diagnosed him with MEN1. Endocrinological tests revealed that his serum prolactin (PRL) and plasma adrenocorticotropic hormone (ACTH) levels were elevated to 1699 ng/mL and 125 pg/mL respectively. Immunohistochemical analysis of the resected pancreatic tumors revealed that the tumors did not express ACTH. Overnight 0.5 and 8 mg dexamethasone suppression tests indicated that his pituitary tumor was a PRL-ACTH-producing plurihormonal tumor. Before transsphenoidal surgery, cabergoline was initiated. Despite no decrease in the volume of the pituitary tumor, PRL and ACTH levels decreased to 37.8 ng/mL and 57.6 pg/mL respectively. Owing to the emergence of metastatic gastrinoma in the liver, octreotide was initiated. After that, PRL and ACTH levels further decreased to 5.1 ng/mL and 19.7 pg/mL respectively. He died from liver dysfunction, and an autopsy of the pituitary tumor was performed. In the autopsy study, histopathological and immunohistochemical (IHC) analysis showed that the tumor was single adenoma and the cells were positive for ACTH, growth hormone (GH), luteinizing hormone (LH) and PRL. RT-PCR analysis showed that the tumor expressed mRNA encoding all anterior pituitary hormones, pituitary transcription factor excluding estrogen receptor (ER) β, somatostatin receptor (SSTR) 2, SSTR5 and dopamine receptor D (D2R). PRL-ACTH-producing tumor is a very rare type of pituitary tumor, and treatment with cabergoline and octreotide may be useful for controlling hormone levels secreted from a plurihormonal pituitary adenoma, as seen in this case of MEN1.

Learning points:

  • Although plurihormonal pituitary adenomas were reported to be more frequent in patients with MEN1 than in those without, the combination of PRL and ACTH is rare.

  • RT-PCR analysis showed that the pituitary tumor expressed various pituitary transcription factors and IHC analysis revealed that the tumor was positive for PRL, ACTH, GH and LH.

  • Generally, the effectiveness of dopamine agonist and somatostatin analog in corticotroph adenomas is low; however, if the plurihormonal pituitary adenoma producing ACTH expresses SSTR2, SSTR5 and D2R, medical therapy for the pituitary adenoma may be effective.

Open access